PCN286 - INCREMENTAL COST-EFFECTIVENESS RATIO FOR THE ANTINEOPLASTIC DRUGS APPROVED AND REJECTED FOR THE VITAL AND ESSENTIAL DRUGS LIST IN 2017 IN RUSSIAdoi:10.1016/j.jval.2018.09.368Omelyanovskiy, V.Avxentyeva, M.Sura, M.Savilova, A.G....
Sergey Khachatryan - Presto (Presto)